Table 3.
Base-case cost-effectiveness results comparing each medication separately
| Costs (£) | QALYs | Incremental costs (£) | Incremental QALYs | ICER: cost per QALY gained (£) | |
|---|---|---|---|---|---|
| Deterministic results—discounted | |||||
| Placebo | £1,729 | 1.3531 | - | - | - |
| Topiramate | £1,624 | 1.3995 | -£104 | 0.0464 | Dominated |
| Placebo | £1,729 | 1.3531 | - | - | - |
| BTA | £3,654 | 1.4294 | £1,925 | 0.0763 | £25,238 |
| Placebo | £1,729 | 1.3531 | - | - | - |
| Fremanezumab (monthly) | £10,155 | 1.4307 | £8,427 | 0.0776 | £108,604 |
| Placebo | £1,729 | 1.3531 | - | - | - |
| Fremanezumab (quarterly) | £10,193 | 1.4224 | £8,465 | 0.0693 | £122,126 |
| Placebo | £1,729 | 1.3531 | - | - | - |
| Eptinezumab 100 | £10,216 | 1.4239 | £8,487 | 0.0708 | £119,796 |
| Placebo | £1,729 | 1.3531 | - | - | - |
| Galcanezumab | £10,640 | 1.4229 | £8,912 | 0.0698 | £127,649 |
| Placebo | £1,729 | 1.3531 | - | - | - |
| Eptinezumab 300 | £27,401 | 1.4403 | £25,672 | 0.0873 | £294,151 |
| Probabilistic results—discounted | |||||
| Placebo | £1,728 | 1.3460 | - | - | - |
| Topiramate | £1,624 | 1.4045 | -£104 | 0.0584 | Dominated |
| Placebo | £1,728 | 1.3460 | - | - | - |
| BTA | £3,654 | 1.4270 | £1,926 | 0.0810 | £23,775 |
| Placebo | £1,728 | 1.3460 | - | - | - |
| Fremanezumab (monthly) | £10,161 | 1.4350 | £8,433 | 0.0890 | £94,748 |
| Placebo | £1,728 | 1.3460 | - | - | - |
| Fremanezumab (quarterly) | £10,196 | 1.4273 | £8,467 | 0.0812 | £104,251 |
| Placebo | £1,728 | 1.3460 | - | - | - |
| Eptinezumab 100 | £10,221 | 1.4199 | £8,492 | 0.0739 | £114,894 |
| Placebo | £1,728 | 1.3460 | - | - | - |
| Galcanezumab | £10,646 | 1.4161 | £8,917 | 0.0701 | £127,279 |
| Placebo | £1,728 | 1.3460 | - | - | - |
| Eptinezumab 300 | £27,411 | 1.4365 | £25,683 | 0.0904 | £284,030 |